Molecular Profile Detail

Profile Name ERBB2 L869R
Gene Variant Detail

ERBB2 L869R (gain of function)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 L869R lung adenocarcinoma predicted - resistant Lapatinib Case Reports/Case Series Actionable In a clinical case study, ERBB2 (HER2) L869R was identified in the lymph node metastasis from a lung adenocarcinoma patient that progressed on Tykerb (lapatinib) therapy (PMID: 27900369). 27900369
ERBB2 L869R colorectal adenocarcinoma predicted - resistant Lapatinib + Trastuzumab Case Reports/Case Series Actionable In a clinical case study, a colorectal carcinoma patient who initially achieved stable disease following treatment with Tykerb (lapatinib) and Herceptin (trastuzumab) developed secondary resistance, presenting with a brain metastasis, and ERBB2 (HER2) L869R was identified in the brain lesion (PMID: 29941010). 29941010
ERBB2 L869R Her2-receptor negative breast cancer predicted - sensitive HER2 Inhibitor Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926). 29420467
ERBB2 L869R breast cancer sensitive HER2 Inhibitor Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771). 28679771
ERBB2 L869R breast cancer sensitive HER2 Inhibitor Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). 28274957
ERBB2 L869R breast cancer sensitive HER inhibitor (Pan) Afatinib Preclinical - Cell culture Actionable In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). 28274957
ERBB2 L869R breast cancer resistant Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369). 27900369
Clinical Trial Phase Therapies Title Recruitment Status
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer Recruiting